Harnessing the Power of the Community to Battle Obesity
This activity is supported by an educational grant from Lilly.
Click Here to Manage Email Alerts
CE Activity Release Date: May 25, 2023
CE Activity Expiration Date: November 24, 2024
Time to Complete activity: 120 minutes
DESCRIPTION
Community Collective: Harnessing the Power of the Community to Battle Obesity is an educational curriculum designed for primary care clinicians to enhance outcomes for individuals with obesity through improved diagnosis and use of anti-obesity medications (AOMs). This enduring series consists of two parts tailored to the educational needs of US clinicians who treat patients with obesity.
Part 1: Importance of Conversations About an Obesity Diagnosis will cover strategies to conduct a thorough diagnosis of obesity, the importance of having a conversation about obesity diagnosis with patients, and expert commentary on how to include shared decision-making in the patient dialogue. Additionally, there will be discussion regarding the evolving paradigm of anti-obesity medications (AOMs).
Part 2: Practical Applications of New and Emerging Data will cover the latest safety and efficacy data for recently approved and emerging AOMs, strategies for the practical application of data into your clinical practice, and management of adverse events. Additionally, there will be discussion regarding the chronic nature of obesity, dispelling myths and stigma surrounding the disease, and approaches to engage patients in shared decision-making.
TARGET AUDIENCE
This CE activity is intended for primary care physicians, NPs, and PAs who treat individuals with obesity.
EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
- Identify risk factors and common medical consequences and comorbidities of the chronic disease of obesity
- Conduct a thorough diagnosis, including waist circumference, for patients who may have overweight/obesity
- Evaluate the safety and efficacy of the most recently approved and emerging AOMs
- Appropriately discuss effective weight loss options, including new and emerging pharmacotherapies, through a shared decision-making approach
AGENDA
Part 1: Importance of Conversations About an Obesity Diagnosis
- Consequences of under-diagnosis
- Making the diagnosis
- How to talk about a diagnosis of overweight/obesity with patients
- Engaging patients in decision-making
- Pros and cons of first-generation AOMs
- Second-generation AOMs
Part 2: Practical Applications of New and Emerging Data
- Treating obesity as a chronic disease
- Safety and efficacy data of most recently approved and emerging AOMs
- Overcoming therapeutic inertia
- Engaging patients in maintenance (continued) treatment decisions
- Monitoring and mitigating adverse events
- Initiating and optimizing therapy
- Questions from the community
ACCREDITATION, SUPPORT AND CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until May 24, 2024. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
Support Statement
This activity is supported by an educational grant from Lilly.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Scott D. Isaacs, MD, FACP, FACE
Adjunct Associate Professor of Medicine
Emory University School of Medicine
Atlanta, GA
Scott D. Isaacs, MD, FACP, FACE, has no relevant financial relationships with ineligible companies to disclose for this educational activity
Planner/Presenter
Robert F. Kushner, MD
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Chicago, IL
Robert F. Kushner, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Altimmune, Boehringer Ingelheim, Lilly, Novo Nordisk, Pfizer, Weight Watchers
Holly F. Lofton, MD, DABOM
Clinical Associate Professor of Surgery and Medicine
Director, Medical Weight Management Program
NYU Langone Weight Management Program
New York, NY
Holly F. Lofton, MD, DABOM, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Novo Nordisk
Research Grant: Eli Lilly, Novo Nordisk
Speakers’ Bureau: Novo Nordisk
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Currax
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
All of the relevant financial relationships of individuals for this activity have been mitigated.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact mvu@mlieducation.org.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
